Sitilop Star of the Year
Awards were given during the Sitilop Master Meeting to acknowledge the outstanding work of the team’s members. Runner-up for the Star of the Year award was Dr Chloe Farrell and the winner was Heather Wilson.
Sitilop Master Meeting
Prof Marios Politis of the Sitilop team hosted the 1st annual Master Meeting with the help of Heather Wilson, Dr Edoardo de Natale and Dr Chloe Farrell. The team had the chance to listen to presentations detailing motivational and intriguing plans for the year to come. Inspiring new ideas were exchanged between its members.
Sitilop was present at the International Congress of Parkinson’s Disease and Movement Disorders
13 members of Sitilop team attended the International Congress of Parkinson’s Disease and Movement Disorders in Nice, France. It was a great opportunity to interact with fellow researchers and collaborators; ideas were exchanged and opinions were expressed between great minds of the field. This environment evolves our understanding on how we can work together with…
Sitilop sponsored travel grants for the International Congress of Parkinson’s Disease and Movement Disorders and the Congress of the European Academy of Neurology
Sitilop sponsored travel grants for early career researchers to enable them to attend and present novel research at the International Congress of Parkinson’s Disease, Nice, France; and Movement Disorders and the Congress of the European Academy of Neurology, Oslo, Norway.
Sitilop is collaborating with Road International
Sitilop is collaborating with Road International to help identify leading compound and mechanism of action for the development of clinical trial.
Sitilop is collaborating with Life Molecular Imaging and Invicro on a new way of evaluating Tau depositions in Progressive Supranuclear Palsy
Progressive Supranuclear Palsy is a rare neurodegenerative disorder characterised by the presence of 4-repeat tau pathology. Progressive Supranuclear Palsy is regarded as a spectrum of different phenotypes characterised by predominant motor, cognitive, speech, or behavioural impairment. No therapy is available for this disease and symptomatic treatment offers only limited benefit. Sitilop is collaborating with Life…
Sitilop is collaborating with Life Molecular Imaging on a new way of evaluating Tau depositions in Alzheimer’s disease
Alzheimer’s disease is the most common cause of dementia worldwide. It is a progressive neurodegenerative disorder for which we currently have no cure or disease modifying therapies to slow disease progression. Alzheimer’s disease is often preceded by a prodromal phase called mild cognitive impairment which is characterised by decline in cognitive performance. Neuropathological hallmarks of…
Sitilop is collaborating with Ligilo
Sitilop is collaborating with Ligilo to develop novel screening tools to help improve the lives of individuals with disorders of the central nervous system by breaking the unemployment barriers.
Sitilop is collaborating with United Neuroscience on a new observational trial in Parkinson’s disease
Parkinson’s disease is the second most common neurodegenerative disorder characterised by the cardinal motor symptoms of bradykinesia, rigidity and tremor; as well as a variety of non-motor symptoms such as sleep problems, cognitive decline and autonomic dysfunction. The neuropathological hallmark of Parkinson’s disease is the presence of α-synuclein (SNCA) aggregates, which form the main components…